Press releases

Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), (“Disruptive Pharma” or the “Company”) will ring the opening bell at Nasdaq Stockholm on 21 August 2026. On the same day, the Company’s shares will begin trading under the new ticker symbol DPHA, replacing GUARD. The bell-ringing ceremony marks the...

27 July 2026 – Guard Therapeutics International AB (publ) (to be renamed Disruptive Pharma AB (publ)) ("Guard Therapeutics" or the "Company") today announces that the reverse takeover (RTO) of Disruptive Pharma Holding AB (publ) ("Disruptive Pharma"), pursuant to the agreement entered into and announced on 10 June 2026, has been completed...

Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today received conditional approval from Nasdaq Stockholm ("Nasdaq") for the continued listing of the Company's shares on Nasdaq First North Growth Market. The application for continued listing was submitted on 11 June 2026 as part of the implementation...

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that it has initiated a structured transaction process regarding the so-called GTX platform, consisting of therapeutic peptides based on the endogenous protein alpha-1-microglobulin (A1M), together with related intellectual property and...

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the ”Company”) has today entered into a conditional agreement with shareholders who together hold approximately 91.3 percent of all outstanding shares in Disruptive Pharma Holding AB (publ) (“Disruptive Pharma”) (the “Majority Shareholders”) regarding the acquisition...